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Abstract
Ci inhibitor (Ci-Inh) catabolism in plasma of patients with
hereditary angioneurotic edema (HANE) was assessed by
measuring the complexes formed by Cl-Inh with its target
proteases (Cis, Factor XIIa, and kallikrein) and a modified
(cleaved) inactive form of Ci-Inh (iCI-Inh). This study was
performed in plasma from 18 healthy subjects and 30 patients
with HANE in remission: 20 with low antigen concentration
(type I) and 10 (from 5 different kindreds) with dysfunctional
protein (type II). Both type-I and type-II patients had in-
creased Ci-Ci-Inh complexes (P < 0.0001), which in type I
inversely correlated with the levels of Cl-Inh (P < 0.001).
iCI-Inh was normal in all type-I patients and in type-I1 pa-
tients from three families with increased Ci-Inh antigen,
whereas iCi-Inh was higher than 20 times the normal values in
patients from the remaining two families with Ci-Inh antigen
in the normal range. None of the subjects had an increase of
either Factor XIIa-Ci-Inh or kallikrein-Ci-Inh complexes.
This study shows that the hypercatabolism of Ci-Inh in
HANE patients at least in part occurs via the formation of
complexes with Ci and that genetically determined differences
in catabolism of dysfunctional Ci-Inh proteins are present in
type-II patients. (J. Clin. Invest. 1990. 85:1215-1220.) com-
plement* contact system * Ci inhibitor catabolism * Ci inhibi-
tor deficiency * dysfunctional Ci inhibitor
Introduction
Hereditary angioneurotic edema (HANE)' is due to the func-
tional deficiency of the inhibitor of the first component of
human complement (C1-Inh) (1). This protease inhibitor is
involved in the regulation of several proteolytic systems in
plasma including the complement system, the contact system
of intrinsic coagulation and kinin release, and the fibrinolytic
system (2). Two phenotypic variants of HANE are known:
type I in which both functional and antigenic CJ-Inh in
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1. Abbreviations used in this paper: CI-Inh, inhibitor of the first com-
ponent of human complement; iCT-Inh, modified (cleaved) inactive
CI-Inh; HANE, hereditary angioneurotic edema; RID, radial immu-
nodiffusion.
plasma is reduced and type II with functional deficiency but
normal or markedly increased antigenic levels due to the pres-
ence of a dysmorphic protein (3, 4). Heterogeneity of the dys-
morphic proteins has been demonstrated among different
type-II HANE families (5). Studies ofin vitro cell cultures have
shown that monocytes from patients with HANE synthesize
- 50% of normal CI-Inh compared with cells from normal
subjects (6), which is in agreement with the autosomal domi-
nant inheritance of the disorder (7). Independently from the
severity of the disease (8), functional CI-Inh in plasma from
patients with HANE ranges between 5 and 30% of the normal
value instead of the expected 50%. In vivo turnover studies
demonstrated that patients with HANE have an increased ca-
tabolism ofnormal C1-Inh along with its reduced synthesis (9).
Lachmann and Rosen have suggested that the discrepancy be-
tween expected and actual functional Cl-Inh levels in HANE
is due to the catabolic behavior of CI-Inh: a level of 50% of
normal cannot be maintained due to consumption of CJ-Inh
via the formation of complexes with its target proteases (Clr,
Cis, Factor XIIa, and kallikrein) (10). Indirect proofthat Cl is
activated in both types ofHANE during asymptomatic periods
comes from the observation that plasma levels of the natural
substrates of activated Cl, i.e., C4 and C2, are reduced (1 1,
12). Zuraw and Curd (13) have found, in type I patients, an
increase ofa modified inactive form ofCl-Inh of 94 kD. Since
this 94-kD CI-Inh was generated in vitro by contact system
activation but not by complement activation, they suggested
that contact system activation may be an important mecha-
nism in the pathophysiology of HANE as first proposed by
Landerman (14). However, evidence that Cl-Inh is indeed
consumed by reacting with its target proteases in asymptom-
atic HANE patients is lacking, as well as is clear-cut proof that
the contact system is hyperactivated (13, 15-19).
Despite the description ofseveral highly sensitive assays for
C1-Inh complexes in plasma (13, 20-24), only few data are as
yet available concerning complex levels in plasma from
HANE patients.
The present study reports on the quantification of Cl-Inh
complexes in plasma from asymptomatic HANE patients and
supports the notion that levels of Cl-Inh in these patients are
lower than expected due to activation of Cl. Moreover, quan-
tification of modified (cleaved) inactive Cl-Inh (iCI-Inh) re-
vealed genetically determined differences in the catabolism of
dysfunctional proteins in patients with type-II HANE.
Methods
Subjects and blood sampling
30 HANE patients, aged 14-66 yr, were studied. 16 were males and 14
were females. The patients (20 type I and 10 type II) were in remission
(attack-free and without treatment for at least 3 mo). 18 healthy donors
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(9 males and 9 females ranging in age between 25 and 62 yr) served as
controls. Blood samples were obtained by clean venipuncture without
stasis and collected in siliconized vacutainer tubes (Becton Dickinson,
Plymouth, UK) to which EDTA (10 mM) and Polybrene (0.05%,
wt/vol) had been added to prevent in vitro activation of the comple-
ment and the contact system (20, 24). Tubes were centrifuged at 1,300
g, at room temperature, for 10 min and plasma was aliquoted and
stored in polystyrene tubes at -70'C until tests were performed.
Procedure
RlAs for Cl-Inh species were performed as described in detail pre-
viously (20, 25-27).
CF-Inh complexes. MAb KOK 12, which binds to both complexed
C1-Inh and iCl-Inh, but not to native C1-Inh, was coupled to Sepha-
rose beads and incubated with plasma samples. After washing the
Sepharose with saline, bound complexes were detected by subsequent
incubation with '25I-labeled polyclonal antiprotease antibodies (125I1
anti-Factor XII, '25I-antikallikrein, or '25I-anti-Cls). After another
washing procedure, Sepharose-bound radioactivity was measured. As
standards in the appropriate assay we used serial dilutions ofplasma in
which a maximal amount of Factor XIIa-Cl-Inh (i.e., 0.375 MM) and
kallikrein-Cl-Inh (i.e., 0.341 MM) complexes was generated by incu-
bation with dextran sulphate and serum in which a maximal amount
ofC1-C 1 -Inh (0.360 M) complexes was generated by incubation with
heat-aggregated human IgG (20, 24, 27). Intra- and interassay coeffi-
cients of variation were < 10%. Details on this as well as on the prepa-
ration and stability of the standards are given elsewhere (20, 27).
CJ-Inh antigen and iCf-Inh. In the assay for C1-Inh antigen, a
MAb (R II) that binds all forms of C1-Inh (native C1-Inh, complexed
C1-Inh, and iCl-Inh) was used. iCI-Inh was measured with a MAb (K
II), that binds to iC1-Inh, but not to native and complexed C1-Inh (25).
Binding of Cl-Inh species to these MAbs was detected using '251-la-
beled polyclonal anti-Cl-Inh antibodies. Levels of antigenic Cl-Inh
and iCl-Inh were expressed in micromolar by reference to pooled
normal plasma that contained 2.5 MM of antigenic CI-Inh and 0.08
AM of iCl-Inh.
Functional Cl-Inh. This assay is based on the principle that only
functional Cl-Inh will bind to Cls. Plasma samples were incubated
with purified Cis coupled to Sepharose. Binding of Cl-Inh to the
Cis-Sepharose was detected by subsequent incubation with 1251-la-
beled polyclonal anti-Cl-Inh. Values for functional Cl-Inh were ex-
pressed in micromolar using pooled normal plasma that contained 2.5
MM of functional C1-Inh as standard.
Prekallikrein and Factor XII were measured by specific RIAs that
have been described previously (20). Values were expressed in micro-
molar by comparison with pooled normal plasma that contained 0.57
MM of prekallikrein and 0.50 MM of Factor XII.
Chromogenic assay for functional Cl-Inh was performed with the
C1-Inh reagent kit ofImmuno (Vienna, Austria). This method is based
on the measurement of chromogenic groups released from pyrogluta-
myl-glycyl-arginin-pNA (Kabi Ab, Stockholm) which is specifically
split by Cls. Intra- and interassay coefficients of variation are < 10%.
Radial immunodiffusion (RID) for Cl-Inh and C4 antigen was
performed according to Mancini et al. (28) (NOR-Partigen; Behring,
Marburg, FRG).
SDS-PAGE and immunoblotting analysis ofCl-Inh. Total Cl-Inh
(with MAb RII) and iCl-Inh (with MAb KII) were immunoprecipi-
tated from plasma by incubating 25 Ml of plasma for 5 h at room
temperature with 80 Mg ofMAb coupled to Sepharose. After a washing
procedure, Sepharose-bound protein was eluted into nonreducing SDS
sample buffer by incubation for 10 min at 100°C. The Sepharose beads
were pelleted and the supernatants ("immunoprecipitates") were sub-
jected to SDS-PAGE (7% wt/vol) slab. After electrophoretic transfer of
proteins from the gel onto nitrocellulose sheets, Cl-Inh species on the
blots were visualized by incubation with MAb RII purified by affinity
chromatography on protein A-Sepharose and radiolabeled with 125I by
lodogen method, followed by autoradiography. Details of the proce-
dures were as described previously (29). The apparent molecular mass
of proteins was estimated by comparison with the high-molecular
weight protein markers of Bio-Rad Laboratories (Richmond, CA).
Statistics
The results were expressed as median and range; the Kruskal Wallis
analysis of variance was performed and the significance of the differ-
ences between groups was assessed by the nonparametric test of Wil-
coxon-Mann-Whitney. A P-value of < 0.05 was considered to indicate
a statistically significant difference.
Results
Median values and ranges ofthe measurements in patients and
healthy controls are presented in Table I. The results showed a
significant correlation between RID and RIA for C1-Inh anti-
gen (n = 48, r = 0.92, x/y = 0.96) and between chromogenic
assay and RIA for functional Cl-Inh (n = 48, r = 0.98, x/y
= 0.99).
Patients with type-I HANE. Plasma levels of antigenic and
functional C1-Inh and of C4 antigen were significantly (P
< 0.0001) reduced as compared with those in healthy volun-
teers. Prekallikrein antigen was slightly decreased in patients
compared with healthy controls, but the difference did not
reach statistical significance. C 1-C1-Inh complexes in plasma
were significantly increased compared with the controls (P
< 0.0001); levels of these complexes inversely correlated with
functional (r = -0.78, P < 0.001; Fig. 1) and antigenic (r
= 0.66, P < 0.001) C1-Inh. Plasma levels of Factor XIIa-C1-
Inh, kallikrein-C1-Inh, and Factor XII in the patients were not
different from those in healthy volunteers.
Patients with type-II HANE. As for type-I patients,
C1-C 1-Inh complexes were significantly increased (P
< 0.0001) compared with the controls, but neither correlated
with functional C I -Inh nor with C -Inh antigen. A significant
increase in plasma levels of iCl-Inh was found (P < 0.005).
When data were assembled for families (Table II), two groups
could clearly be identified: group 1 (family a and b) with Cl-
Inh antigenic levels (determined by RID) that ranged between
51 and 67% of normal, and group 2 (family c, d, and e) with
Cl-Inh levels exceeding 100%. The two groups markedly dif-
fered in iCl-Inh levels which were normal in group 2 and
higher than 20 times the normal value in group 1. Other mea-
surements were similar in both groups. In group 1, levels of
antigenic Cl-Inh obtained with the RIA appeared slightly
higher compared with those obtained by RID.
SDS-PAGE analysis ofdysfunctional CJ-Inh proteins. Im-
munoprecipitates of Cl-Inh species from plasma of patients
with type-Il HANE were subjected to SDS-PAGE and im-
munoblot analysis (Fig. 2). Immunoblots of antigenic Cl-Inh
(RII-immunoprecipitate) from pooled normal plasma showed
a major protein band of M, 110,000, whereas those from
plasma of all patients from group 1 revealed pronounced pro-
tein bands ofMr 1 10,000 and 98,000. Immunoblots ofiCl-Inh
(KII-immunoprecipitates) from pooled normal plasma re-
vealed only a faint protein band of Mr 98,000. In contrast,
pronounced bands of Mr 98,000 were observed on immuno-
blots of iCl-Inh from patients' plasma samples of group 1.
Immunoblot analysis of antigenic Cl-Inh from plasma of pa-
tients from family c and d (group 2) revealed a major protein
band of Mr 1 10,000 together with a band of Mr 180,000,
whereas no protein bands were observed on immunoblots of
iCl-Inh from these plasma samples. The results of RIAs that
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Table I. Complement and Contact System Parameters in Healthy Subjects and HANE Patients in Basal Condition
Healthy subjects Type-I HANE Type-l1 HANE
median (range) median (range) median (range)
n= 18 n=20 n= 10
Functional CT-mnh (chromogenic) % 94 16* 15*
(69-119) (0-37) (4-30)
Cy-Inh antigen (RIA) AM 2.19 0.49* 2.94**
(1.30-3.45) (0.08-0.73) (2.35-6.55)
iC--Inh (RIA) MM 0.08 0.09 1.04**
(0.06-0.13) (0.03-0.13) (0.05-3.77)
C4 antigen (RID) % 99 19* 21*
(67-130) (0-67) (9-55)
C--CT-Inh (RIA) MM 0.007 0.0 13* 0.0 17*
(0.001-0.011) (0.003-0.028) (0.008-0.028)
Kallikrein-CT-Inh (RIA) AM 0.0002 <0.0002 <0.0002
(<0.0002-0.0005) (<0.0002) (<0.0002-0.0004)
Factor XIIa-C1-Inh (RIA) AM <0.0002 <0.0002 <0.0002
Prekallikrein (RIA) MM 0.50 0.43 0.49
(0.35-0.627) (0.31-0.62) (0.34-0.62)
Factor XII (RIA) AM 0.49 0.48 0.49
(0.18-0.81) (0.21-0.70) (0.36-0.68)
%= percentage of normal human pooled plasma. Statistical significance vs. normals: *P < 0.0001, **P < 0.005.
specifically detect dimers of albumin and C1
that plasma of patients from family c and d
levels of these dimers (unpublished observation
band of Mr 180,000 observed on the blots is cc
with.
Discussion
In this study we demonstrated elevated pla
Cl-Cl-Inh complexes in asymptomatic patiel
herited deficiency ofC I -Inh. In patients with tyl
levels of these complexes significantly correla
0.03
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Figure 1. Correlation between plasma levels of functic
determined by chromogenic assay, and Cl-Cl-Inh co]
type-I HANE patients.
[-Inh indicated genic and functional CI-Inh (P < 0.001). These observations
contained high suggest that Cl activation is at least in part responsible for the
n). The protein increased catabolism of Cl-Inh found in asymptomatic pa-
)mpatible here- tients with HANE (9), as proposed by Curd et al. (30), and thus
for the apparent discrepancy between expected and actual
levels of functional CI-Inh in this heterozygous disorder (10).
A previous study, using an SDS-PAGE and immunoblotting
technique, reported increased levels of C I -C I -Inh complexes
isma levels of in type-I HANE patients, but no statistical correlation with
nts with an in- Cl-Inh levels was performed (13). Our double antibody assay
pe-I HANE the allows a direct quantification of these complexes and provides
ted with anti- specificity by the use of a MAb that binds complexed CJ1-Inh.
In vitro generation of complexes is avoided by drawing blood
samples into EDTA and polybrene, a procedure that prevents
activation of the contact system and the complement system
via the classical pathway (20, 24, 27, 31).
To our knowledge, no data on the clearance of Cl-Inh
complexes in humans have been published. Recently, we esti-
n=20 mated an apparent t12 time of clearance of - 50 min, for both
r=-0.78 Factor XIIa-Cl-Inh and kallikrein-CJ-Inh complexes, from
p<0.001 sequential measurements of these complexes in patients with
sepsis (20) and we assume that Cl-Cl-Inh complexes also
have a similar t112. Inasmuch as the actual t1/2 may be much
shorter and may vary among different patients' groups, the
contribution of C1 activation to the catabolism of CY-Inh in
HANE patients is difficult to assess. Quastel et al. have shown
that the catabolism of Cl-Inh in HANE is increased by - 1%
of the plasma pool per hour compared with healthy individ-
uals: the fractional catabolic rate was 3.5% of plasma pool per
hour in HANE patients, vs. 2.5% in healthy controls (9). Based
30 35 40 on the median levels of CI-Cl-Inh and of Cl-Inh antigen as
measured by RIA (Tables I and II), and considering that the
nal Cl-Inh, actual composition of C I -C I -Inh is C I rC I s(C1 -Inh)2, the rel-
mplexes in 20 ative amount of CJ-Inh complexed to CI was 0.6% in healthy
subjects and 5.3% in type-I HANE patients. These data suggest
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Table II. Complement Parameters in Type II HANE Patients
Functional CT-Inh
Cr-Inh Cj-Inh antigen antigen iCT-Inh Cj-Cj-Inh
Name Family (chromogenic) (RID) (RIA) (RIA) (RIA)
% % % AM AM
Group I
A.C. a 16 51 96 2.23 0.014
M.C. a 17 67 108 3.77 0.025
P.M. b 14 56 94 1.89 0.012
I.C. b 27 63 121 3.01 0.028
L.C. b 13 52 99 2.25 0.026
median 16 56* 99** 2.25* 0.025
(range) (13-27) (51-67) (94-121) (1.89-3.77) (0.012-0.028)
Group 2
P.P. c 30 314 262 0.05 0.011
D.C. d 14 242 226 0.19 0.020
S.T. d 4 242 125 0.10 0.008
R.B. e 6 117 114 0.09 0.020
M.R.B. e 26 194 160 0.07 0.012
median 14 242 160 0.09 0.012
(range) (4-30) (117-314) (114-262) (0.05-0.19) (0.008-0.020)
Group 1 (family a and b) includes patients with elevated concentrations of iCp-Inh and with Cl-Inh antigen, measured by RID, below 100%.
Group 2 (family c, d, and e) includes patients with normal concentrations of iC1-Inh and with C,-Inh antigen, measured by RID, above 100%
of normal pooled plasma. Patients are designated with their name initials. Percentage values are obtained referring to a curve of serial dilutions
of plasma pooled from 30 healthy individuals. Micromolar values are obtained as described in Methods. Median value for Cl-Inh antigen
with RID in normals is 98% (range 63-137%), median values for other parameters are reported in Table I. Statistical significance vs. group 2:
*P= 0.0079; **P = 0.0 159.
that the increase in Cl-Inh catabolism in type-I HANE is at plexes from the circulation. A new approach, such as with
least in part due to complex formation with C1. recently developed methods (19), may prove useful in defining
In this study, we did not find an increase of Factor the role of contact activation envisaged in HANE patients
XIIa-Cl-Inh or kallikrein-Cl-Inh complexes despite the high outside acute swellings (13, 14).
sensitivity of the assays that can detect 0.05% activation of Patients with type-II HANE could be divided into two
plasma Factor XII and prekallikrein (20). These results suggest groups based on plasma levels ofCl-Inh antigen and iCl-Inh.
that the extent ofcontact activation in HANE patients in basal In group 1, antigenic C1-Inh, as measured by RID, ranges
condition is not enough to overcome the clearance of com- between 51 and 67% of normal and the concentration of iC1-
D.C. P.P.
KI Rill Kil Rll
P.M. A.C. M.C. Normal .C. L.C.
RIl K RH KiI Ri Kil R11 K Rill Kil Ril Kil
* * _ 116
97 j , 1
43_
Figure 2. Immunoblotting ofCI-Inh in
pooled normal plasma and in patients with
type-II HANE, group I (right) and group 2
(left), identified by their initials. Total CI-
Inh antigen and iC1-Inh were immunopre-
cipitated from plasma by Sepharose-cou-
pled MAb to total C1-lnh (RII) and to iCI-
Inh (KII), respectively, and separated on
nonreduced 7% SDS-PAGE. After electro-
transfer to nitrocellulose and immunoblot-
tingby '251-labeled MAb RII, bands were
visualized by autoradiography.
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Inh is at least 20 times higher than in pooled normal plasma
(2,360-4,718%). The measurement of CJ-Inh antigen by RIA
in this group resulted in significantly higher levels than those
found by RID. This difference may be ascribed to the presence
of high levels of iCI-Inh, which is recognized by the monoclo-
nal antibody used in the RIA, but poorly detected by the poly-
clonal antibody used in RID, as demonstrated by immuno-
blotting experiments (data not shown). In group 2, Cl-Inh
antigen exceeded 100% (117-314%) and iCl-Inh is normal or
only slightly increased (66-238%). The immunoblotting ex-
periments revealed that CI-Inh in group 1 was, for the major
part, degraded into a form with Mr 98,000, whereas no such
bands were observed on blots of CT-Inh from plasma of pa-
tients from group 2. We think that these differences reflect two
different molecular mechanisms that may underlie type-Il
HANE. In group 1 (relatively low antigenic C1-Inh and high
iCl-Inh levels) the mutation in the CJ-Inh gene probably
yields a CJ-Inh protein which still can form complexes with
target proteases such as Cis, but these complexes are not stable
and are rapidly hydrolyzed into an active protease and iCi-
Inh. The mutations that underlie this form of HANE thus
render Cl-Inh a true substrate for target proteases. Studies
performed with dysfunctional molecules purified from pa-
tients with type-II HANE, suggest that some of the dysfunc-
tional molecules indeed behave like substrates for target pro-
teases (5, 32). For example, four of the eight dysfunctional
C1-Inh molecules studied by Donaldson et al. (32) were
cleaved by kallikrein, and did not form stable complexes with
this target protease. We have recently prepared a recombinant
CJ-Inh protein with an arginine at position P3. This mutant
protein does not form stable complexes with kallikrein, but
instead is rapidly degraded by this protease (Eldering, E., C. C.
M. Huijbregts, J. H. Nuijens, and C. E. Hack, manuscript in
preparation). In group 2, the mutant C1-Inh protein probably
does not interact with target proteases at all and accounts for
higher levels ofC1-Inh antigen due to a slower catabolism. The
type-II group-2 patients in whom we detected high plasma
levels of dimers between albumin and CI-Inh are very likely to
have a substitution of P1 arginine by cysteine (33). The differ-
ences in type-II Hane patients of groups 1 and 2, as well as the
variability in C1-Inh catabolism revealed by in vivo turnover
studies (9), may thus reflect different mutations at the reactive
center P1 (33-35) or other functionally important residues. In
type-II patients, C!-Cl-Inh complexes did not significantly
correlate with the levels of CJ-Inh function. These complexes
were higher in group I than in group 2 (Table II), although this
difference was not statistically significant probably because of
the small number of cases. It is possible that part of the com-
plexes measured in group-I patients is represented by the un-
stable complexes formed by the dysfunctional protein as pro-
posed above.
Zuraw and Curd (13) studied nine type-I and 2 type-Il
HANE patients, using a monoclonal antibody that recognizes
both native and cleaved CJ-Inh. In that study, the ratio be-
tween inactive and total C1-Inh was increased in type-I pa-
tients and was normal in type II. Our present data cannot be
directly compared because we used a different method (RIA
vs. immunoblotting) and a different monoclonal antibody that
does not react with the native Cl-Inh (25). However, our re-
sults in type-I patients, as well as those from Zuraw and Curd,
demonstrate that relative amount of modified inactive C1-Inh
is increased compared with normal when referred to total con-
tent of CI-Inh, which is markedly reduced in these patients.
Therefore, the increase in iCl-Inh, which results from the in-
teraction of CJ-Inh with as yet unknown proteases (25), is
consistent with the hypercatabolism of CJ-Inh, but cannot
discriminate the catabolic pathway. For type II, it appears that
both patients studied by Zuraw and Curd ( 13) belong to those
that we called group 2 and we agree with their suggestion that
the amount of catabolic product is dependent on the ability of
the mutant C1-Inh to interact with proteases.
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